Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
Open accessAbstract
The efficacy of ALK inhibitors in patients with ALK-mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human neuroblastoma cell lines and xenograft models expressing activated ALK. Herein, we report that combined inhibition of ALK and MDM2 induced a complementary set of anti-proliferative and pro-apoptotic proteins. Consequently, this combination treatment synergistically inhibited proliferation of TP53 wild-type neuroblastoma cells harboring ALK amplification or mutations in vitro, and resulted in complete and durable responses in neuroblastoma xenografts derived from these cells. We further demonstrate that concurrent inhibition of MDM2 and ALK was able to overcome ceritinib resistance conferred by MYCN upregulation in vitro and in vivo. Together, combined inhibition of ALK and MDM2 may provide an effective treatment for TP53 wild-type neuroblastoma with ALK aberrations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For neuroblastoma cells, MDM2 inhibitors cooperate with anaplastic lymphoma kinase (ALK) inhibition.
“For neuroblastoma cells, MDM2 inhibitors cooperate with anaplastic lymphoma kinase (ALK) inhibition48.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,991 · see citing works
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796 · see citing works
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · see citing works
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · see citing works
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · see citing works
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026 · see citing works
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956 · see citing works
Cui, J. J., Tran‐Dubé, M., Shen, H., Nambu, M. D., Kung, P., Pairish, M., Jia, L., Meng, J. J., Funk, L. A., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 953 · see citing works
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 941 · see citing works
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 915 · see citing works
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix‐Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 893 · see citing works
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893 · see citing works
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 847 · see citing works
Self-citationMossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K. D., Ruffner, K. L., Laliberté, J., Rolland, D. C. M., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 708 · see citing works
Johnson, T. W., Richardson, P., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y., Dinh, D. M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 616 · see citing works
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K. E., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 473 · see citing works
Self-citationBoon, K., Caron, H. N., van Asperen, R., Valentijn, L. J., Hermus, M.-C., Sluis, P. V., Roobeek, I., Weis, I., Voûte, P. A., Schwab, M., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1383 · Cited by 439 · see citing works
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 422 · see citing works
Self-citationBresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H. T., Laudenslager, M., Rappaport, E. F., Wood, A., McGrady, P., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388 · see citing works
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Pérez‐Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 363 · see citing works
Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J. E., Capelletti, M., Wang, L., Gray, N. S., Wilner, K. D., Christensen, J. G., Demetri, G. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 333 · see citing works
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 325 · see citing works
Brouwer, S. D., Preter, K. D., Kumps, C., Zabrocki, P., Porcu, M., Westerhout, E. M., Lakeman, A., Vandesompele, J., Hoebeeck, J., Maerken, T. V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2660 · Cited by 277 · see citing works
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K. A., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237 · see citing works
Infarinato, N. R., Park, J. H., Krytska, K., Ryles, H. T., Sano, R., Szigety, K. M., Li, Y., Zou, H. Y., Lee, N. V., Smeal, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1056 · Cited by 183 · see citing works
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A. R., Preter, K. D., Kumps, C., Wilde, B. D., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 180 · see citing works
The p53 pathway and its inactivation in neuroblastoma
Tweddle, D. A., Pearson, A. D. J., Haber, M., Norris, M. D., Xue, C., Flemming, C. L., & Lunec, J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00088-0 · Cited by 171 · see citing works
McTigue, M. A., Deng, Y., Liu, W., Brooun, A., & Stewart, A. (2014) · Worldwide Protein Data Bank · doi:10.2210/pdb4ctb/pdb · Cited by 170 · see citing works
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Carr‐Wilkinson, J., O’Toole, K., Wood, K. M., Challen, C., Baker, A., Julian Board, Evans, L. E., Cole, M. F., Cheung, N. V., Boos, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1865 · Cited by 161 · see citing works
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 154 · see citing works
Maerken, T. V., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. J., Cuvelier, C. A., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 120 · see citing works
Li, F., Huynh, H. T., Li, X., Ruddy, D. A., Wang, Y., Ong, R., Chow, P. K. H., Qiu, S., Tam, A., Rakiec, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0763 · Cited by 107 · see citing works
Self-citationCrizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Krytska, K., Ryles, H. T., Sano, R., Raman, P., Infarinato, N. R., Hansel, T. D., Makena, M. R., Song, M. M., Reynolds, C. P., & Mossé, Y. P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0379 · Cited by 105 · see citing works
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Wood, A., Krytska, K., Ryles, H. T., Infarinato, N. R., Sano, R., Hansel, T. D., Hart, L. S., King, F. J., Smith, T. R., Ainscow, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1114 · Cited by 98 · see citing works
Self-citationA distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · see citing works
Self-citationMYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
Gamble, L. D., Kees, U. R., Tweddle, D. A., & Lunec, J. (2011) · Oncogene · doi:10.1038/onc.2011.270 · Cited by 82 · see citing works
Chen, L., Rousseau, R. F., Middleton, S. A., NICHOLS, G. L., Newell, D. R., Lunec, J., & Tweddle, D. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3504 · Cited by 80 · see citing works
Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo
Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J. M., Ludwig, A. D., & Shohet, J. M. (2009) · Neoplasia · doi:10.1593/neo.09466 · Cited by 60 · see citing works
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0429 · Cited by 56 · see citing works
Self-citationGeoerger, B., Schulte, J. H., Zwaan, C. M., Casanova, M., Fischer, M., Moreno, L., Trahair, T. N., Jiménez, I., Kang, H. J., Pappo, A. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.10005 · Cited by 37 · see citing works
Bağcı, Ö., Tümer, S., Olgun, N., & Altungöz, O. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.013 · Cited by 27 · see citing works
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 419 · see citing works
The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
Hou, H., Sun, D., & Zhang, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0937-4 · Cited by 232 · see citing works
ALK in Neuroblastoma: Biological and Therapeutic Implications
Trigg, R. M., & Turner, S. D. (2018) · Cancers · doi:10.3390/cancers10040113 · Cited by 155 · see citing works
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 147 · see citing works
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope
Zafar, A., Wang, W., Liu, G., Xian, W., McKeon, F., Zhou, J., & Zhang, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.023 · Cited by 107 · see citing works
Schmelz, K., Toedling, J., Huska, M. R., Cwikla, M. C., Kruetzfeldt, L.-M., Proba, J., Ambros, P. F., Ambros, I. M., Boral, Ş., Lodrini, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26870-z · Cited by 100 · see citing works
Molecular mechanisms and therapeutic targets in neuroblastoma
Johnsen, J. I., Dyberg, C. H., Fransson, S. M., & Wickström, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.023 · Cited by 74 · see citing works
Mlakar, V., Morel, E., Mlakar, S. J., Ansari, M., & Gumy‐Pause, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01967-x · Cited by 69 · see citing works
Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance
Lu, J., Zhao, H., Yu, C., Kang, Y., & Yang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648491 · Cited by 59 · see citing works
Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
Aubry, A., Galiacy, S. D., & Allouche, M. (2019) · Cancers · doi:10.3390/cancers11030275 · Cited by 47 · see citing works
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46 · see citing works
The ALK receptor in sympathetic neuron development and neuroblastoma
Janoueix‐Lerosey, I., Lopez‐Delisle, L., Delattre, O., & Rohrer, H. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2784-8 · Cited by 41 · see citing works
Emdal, K. B., Pedersen, A.-K., Bekker‐Jensen, D. B., Lundby, A., Claeys, S., Preter, K. D., Speleman, F., Francavilla, C., & Olsen, J. V. (2018) · Science Signaling · doi:10.1126/scisignal.aap9752 · Cited by 42 · see citing works
Trigg, R. M., Lee, L. C., Prokoph, N., Jahangiri, L., Reynolds, C. P., Burke, G. A. A., Probst, N. A., Han, M., Matthews, J. D., Lim, H. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13315-x · Cited by 41 · see citing works
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40 · see citing works
Perri, P., Ponzoni, M., Corrias, M. V., Ceccherini, I., Candiani, S., & Bachetti, T. (2021) · Cancers · doi:10.3390/cancers13215528 · Cited by 40 · see citing works
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Tucker, E. R., Jiménez, I., Chen, L., Bellini, A., Gorrini, C., Calton, E. A., Gao, Q., Che, H., Poon, E., Jamin, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2274 · Cited by 34 · see citing works
Palbociclib releases the latent differentiation capacity of neuroblastoma cells
Ferguson, K. M., Gillen, S. L., Chaytor, L., Poon, E., Marcos, D., Gomez, R. L., Woods, L. M., Mykhaylechko, L., Elfari, L. M., Costa, B. M. D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.08.028 · Cited by 33 · see citing works
Wu, D., Pang, S., Berg, J., Mei, Y., Ali, A. S. M., Röhrs, V., Tolksdorf, B., Hagenbuchner, J., Ausserlechner, M. J., Deubzer, H. E., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314171 · Cited by 32 · see citing works
Zanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 29 · see citing works
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 27 · see citing works
Peitz, C., Sprüssel, A., Linke, R. B., Astrahantseff, K., Grimaldi, M., Schmelz, K., Toedling, J., Schulte, J. H., Fischer, M., Messerschmidt, C., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.07.006 · Cited by 25 · see citing works
Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C. E., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0710 · Cited by 24 · see citing works
Brenner, A. K., & Gunnes, M. W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091427 · Cited by 23 · see citing works
Li, T., Deng, Y., Shi, Y., Tian, R., Chen, Y., Zou, L., Kazi, J. U., Rönnstrand, L., Feng, B., Chan, S. O., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0397-7 · Cited by 21 · see citing works
Cheng, T., Gu, Z., Song, D., Liu, S., Tong, X., Wu, X., Lin, Z., & Hong, W. (2020) · Journal of Cancer · doi:10.7150/jca.49391 · Cited by 20 · see citing works
Miyazaki, M., Otomo, R., Matsushima‐Hibiya, Y., Suzuki, H., Nakajima, A., Abe, N., Tomiyama, A., Ichimura, K., Matsuda, K., Watanabe, T., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0059-0 · Cited by 20 · see citing works
Developing preclinical models of neuroblastoma: driving therapeutic testing
Ornell, K. J., & Coburn, J. M. (2019) · BMC Biomedical Engineering · doi:10.1186/s42490-019-0034-8 · Cited by 19 · see citing works
Pucci, P., Lee, L. C., Han, M., Matthews, J. D., Jahangiri, L., Schlederer, M., Manners, E., Sorby‐Adams, A., Kaggie, J. D., Trigg, R. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47771-x · Cited by 17 · see citing works
Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs
Vagapova, E. R., Kozlov, M. V., Lebedev, T. D., Ivanenko, K. A., Leonova, O. G., Попенко, В. И., Spirin, P., Kochetkov, S. N., & Prassolov, V. (2021) · Biomedicines · doi:10.3390/biomedicines9121846 · Cited by 17 · see citing works
Preclinical Models of Neuroblastoma—Current Status and Perspectives
Krawczyk, E., & Kitlinska, J. B. (2023) · Cancers · doi:10.3390/cancers15133314 · Cited by 16 · see citing works
Maser, T. P., Zagorski, J. W., Kelly, S. J., Ostrander, A., Goodyke, A., Nagulapally, A. B., Bond, J. P., Park, Y., & Sholler, G. S. (2020) · Cancer Medicine · doi:10.1002/cam4.3407 · Cited by 14 · see citing works
Systematic identification of ALK substrates by integrated phosphoproteome and interactome analysis
Adachi, J., Kakudo, A., Takada, Y., Isoyama, J., Ikemoto, N., Abe, Y., Narumi, R., Muraoka, S., Gunji, D., Hara, Y., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101202 · Cited by 12 · see citing works
Yang, Y., Yang, H., Gao, Y., Yang, Q., Zhu, X., Miao, Q., Xu, X., Li, Z., & Zuo, D. (2024) · Cell Biology International · doi:10.1002/cbin.12249 · Cited by 10 · see citing works
Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines
Hagiwara, K., Tokunaga, T., Iida, H., & Nagai, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13504 · Cited by 10 · see citing works
Multiple approaches to repurposing drugs for neuroblastoma
Rank, L., Puhl, A. C., Havener, T. M., Anderson, E. N., Foil, D. H., Zorn, K. M., Monakhova, N., Riabova, O., Hickey, A. J., Makarov, V., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117043 · Cited by 11 · see citing works
Xenograft models for pediatric cancer therapies
McNerney, K. O., & Teachey, D. T. (2021) · Faculty Reviews · doi:10.12703/r/10-11 · Cited by 3 · see citing works
Gambacurta, A., & Raschellà, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0728-1 · Cited by 2 · see citing works
Resistance mechanisms to ALK TKIs in tumors other than lung cancer
Mologni, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00005-x · Cited by 1 · see citing works
Holland, S. H. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24324 · Cited by 1 · see citing works
Zhang, L., & Baruchel, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00003-6
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · doi:10.53846/goediss-7056
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.22522659.v1
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.c.6543453.v1
- Authors
- Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., Kasibhatla, S., Li, N., Williams, J. A., Sellers, W. R., Huang, A., & Li, F.
- Affiliations
- Novartis Institutes for BioMedical Research (CH)
- Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Genomics Institute of the Novartis Research Foundation (US)
- Corresponding author
- Li, Fang
- ORCID
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2017-04-20
- Volume
- 6
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC5435462
- OpenAlex
- W2606636950
- Cited by
- 45
- References
- 45
- Citations by year
- 2024: 4 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 5 · 2019: 8 · 2018: 9
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- eLife (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Neurology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- ALK inhibition, MDM2 inhibition, combination therapy, ALK amplification, apoptosis, anticancer activity, xenograft models, synergistic antiproliferative effect
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Mice, Nude, Neoplasm Transplantation, Neuroblastoma, Pyrimidines, Sulfones, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, Proto-Oncogene Proteins c-mdm2, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
